Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder

• Status: Unknown status
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

Null hypothesis of the trial is that there is no difference between solifenacin and oxybutynin with respect to efficacy, side effects, patient satisfaction and quality of life measures in patients with overactive bladder.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Adana Numune Training and Research Hospital
• Collaborators: Akdeniz University; Ankara University; Baskent University; Cukurova University; Gaziosmanpasa University; Inonu University; Kahramanmaras Sutcu Imam University; Kocaeli University; University of Gaziantep
• Treatments: Mandelic Acids; Oxybutynin; Solifenacin Succinate

Criteria

Inclusion Criteria: Women between 18-70 years of age, diagnosed to have overactive bladder (presence of at least two of the following three main criteria: urgency, urge incontinence, frequency and nocturia)

Exclusion Criteria: Presence of stress urinary incontinence, patients who are still using a drug for overactive bladder, pregnant women, women in postpartum period (women on lactation), patients who have closed angle glaucoma, patients with chronic constipation, having allergy to the ingredients of the drugs, patients having the contraindicated conditions listed in the printed instructions of the drugs.

-